About this episode
Do GLP-1 medications cause muscle loss? And why can two people taking the same obesity medication have very different results?
In the first Weight & Measure Research Roundup, Zach breaks down three new papers in under 14 minutes. We start with a study comparing tirzepatide and semaglutide: the difference in lean mass loss narrowed from 2.1 to 0.1 percentage points after researchers accounted for total weight lost. Zach explains what a body composition scan can tell us, why lean mass and skeletal muscle are different, and why strength and physical function belong in the conversation.
We also look at whether rare genetic variants might help explain differences in semaglutide response, and what a map of 517 GLP-1 trials leaves unanswered about using Obesity Management Medications (OMMs) before or after metabolic & bariatric surgery.
Chapters
00:00 Welcome to the Research Roundup
01:32 GLP-1 muscle loss headlines: What did the study measure?
04:57 Could genetics influence semaglutide response?
08:24 What 517 GLP-1 trials tell us about medication and surgery
11:24 What should we measure beyond weight loss?
Studies discussed
Tirzepatide vs. semaglutide and lean mass in routine care — npj Exercise Medicine and Health
Rare GLP1R variants and response to semaglutide or tirzepatide — Nature Metabolism
A systematic evidence map of 517 GLP-1 clinical trials — Obesity Surgery
Would you like more short research episodes between our regular conversations? Tell us what question you’d like us to cover next. Follow Weight & Measure wherever you listen, subscribe on YouTube, and read the weekly Research Roundup.
More science. Less stigma.